U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 1997 ____ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1994 Commission File Number. 0-21819 HealthDesk Corporation (Exact name of Company as specified in charter) California 94-3165144 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 2560 Ninth Street, Suite 220, 94710 Berkeley, California (Zip Code) (Address of principal executive offices) (510) 883-2160 (Company's telephone number, including area code) Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No___ As of October 31, 1997, there were 5,392,845 shares of the Company's Common Stock outstanding, 1,955,000 Redeemable Warrants outstanding and 340,000 Underwriter's Warrants outstanding. Transitional Small Business Disclosure Format Yes___ No X ________________________________________________________________________________ INDEX Part I Page Item 1 Financial Statements ............................................. 3 Item 2 Management's Discussion and Analysis or Plan Operation............ 3 Part II Item 6 Exhibits and Reports on Form 8-K.................................. 6 Part I Item 1. Financial Statements. The following Financial Statements are filed with this report as pages F-1 through F-7 following the signature page: Index to Interim Financial Statements Condensed Balance Sheets Condensed Statements of Operations Condensed Statements of Shareholders' Equity (Deficit) Condensed Statements of Cash Flows Notes to Condensed Financial Statements Item 2. Management's Discussion and Analysis or Plan Operation. The Company's operating performance each quarter is subject to various risks and uncertainties as discussed in the Company's Form 10-KSB for the year ended December 31, 1996. The following discussion should be read in conjunction with the section entitled "Factors Affecting the Company's Business, Operating Results and Financial Condition" in the Form 10-KSB. The information set forth in "Management's Discussion and Analysis of Financial Condition and Results of Operations" below includes "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and is subject to the safe harbor created by the section. Readers are cautioned not to place undue reliance on these forward-looking statements as they speak only as of the date hereof. Overview The Company was organized in August 1992. Since inception, the Company has been engaged primarily in product development activities. The Company's initial product was introduced in early 1993 and the Company has not yet proven to be commercially viable. The Company has not yet generated any meaningful revenues, and will not generate any meaningful revenues until after the Company successfully completes development and market testing of HealthDesk OnLine and attracts and retains a significant number of subscribers. For the period August 28, 1992 (inception) to September 30, 1997, the Company incurred a cumulative net loss of $9,373,154. Since September 30, 1997, the Company has continued to incur increasing and significant losses and anticipates that it will continue to incur significant losses until, at the earliest, the Company generates sufficient revenues to offset the substantial up-front expenditures and operating costs associated with developing and commercializing its products. In January 1997 the Company completed an initial public offering ("IPO") raising net proceeds of $7,018,788 through the issuance of 1,700,000 shares of Common Stock and 1,955,000 Warrants. The statements regarding the Company's future cash requirements are forward looking statements that are subject to risks and uncertainties which could result in the Company's inability to meet its funding requirements for the time period indicated. Software development costs (consisting primarily of salaries and related expenses) incurred prior to establishing technological feasibility are expensed in accordance with Financial Accounting Standards Board (FASB) Statement No. 86. In accordance with FASB 86, the Company will capitalize software development costs at such time as the technological feasibility of the product has been established. In February 1997, Statement of Financial Accounting Standards No. 128 "Earnings Per Share" (FAS 128) was issued and is effective for the Company's year ending December 31, 1997. In March 1997, Statement of Financial Accounting Standards No. 129, "Disclosure of Information About Capital Structure" was issued and is effective for the Company's year ending December 31, 1997. In June 1997, Statement of Financial Accounting Standards No. 130 "Reporting Comprehensive Income" and Statement of Financial Accounting Standards No. 130 3 "Disclosures About Segments of An Enterprise and Related Information" were issued and are effective for the year ending December 31, 1998. The Company has not determined the impact of the implementation of these pronouncements. Recent Events In September 1997, the Company released an upgraded client version of HealthDesk OnLine 2.0, the first software product designed to put the power of general health management firmly into the hands of the consumers. HealthDesk OnLine features easy-to-use Windows based software designed to develop personal medical records and health management programs and educational, health related information from the Company's private Website and over the Internet. Also in September 1997, the Company entered into a three (3) year marketing agreement with HBO & Company of Atlanta, Georgia. The contract is a market limited exclusive agreement to distribute HealthDesk OnLine products to specified markets. The HealthDesk OnLine products distributed through HBO & Company will include the general health focused HealthDesk OnLine and HealthDesk OnLine for Diabetes, both currently on the market as well as other HealthDesk products to be developed. The contract's exclusivity provisions are maintained based on HBO & Company meeting certain performance criteria over the next three years. Results of Operations Revenue increased from $154 for the three months ended September 30, 1996 to $150,047 for the three months ended September 30, 1997, and revenue increased from $6,170 for the nine months ended September 30, 1996 to $376,090 for the nine months ended September 30, 1997. These increases were primarily attributable to an increase in development fee revenue associated with a progress payment for a delivery of a version of HealthDesk OnLine for Diabetes. During 1996, the Company focused its efforts on the initial development of HealthDesk OnLine and reduced its marketing and sales efforts relating to its original HealthDesk product. Product development costs increased by 20.5% from $398,823 for the three months ended September 30, 1996 to $480,477 for the three months ended September 30, 1997, and product development costs increased by 49.5% from $1,194,038 for the nine months ended September 30, 1996 to $1,785,408 for the nine months ended September 30, 1997. These increases in expenditures were principally related to the expansion of the programming staff and associated costs related to the development of HealthDesk OnLine version 2.0 and HealthDesk OnLine for Diabetes during the three months and nine months ended September 30, 1997. To date, all product development costs have been expensed as incurred. The Company believes that significant investments in product development will be incurred to enhance the functionality of HealthDesk OnLine and enhance the investment in new disease and lifestage modules. Sales and marketing costs increased by 1.1% from $341,425 for the three months ended September 30, 1996 to $345,122 for the three months ended September 30, 1997, and sales and marketing costs increased by 38.1% from $836,291 for the nine months ended September 30, 1996 to $1,154,531 for the nine months ended September 30, 1997. These increases resulted primarily from the hiring of additional marketing personnel, associated collateral, travel and entertainment expenses in connection with the marketing of HealthDesk OnLine for Diabetes during the first nine months of 1997. The Company anticipates that sales and marketing costs will increase in future periods, as the Company expands its marketing efforts in support of the agreement with HBO & Company. General and administrative costs decreased by 16.1% from $119,243 for the three months ended September 30, 1996 to $100,078 for the three months ended September 30, 1997, and general and administrative costs decreased by 26.7% from $562,986 for the nine months ended September 30, 1996 to $412,683 for the nine months ended September 30, 1997. These decreases were primarily attributable to a change in the allocation of resources to marketing and development activities and the write-off of deferred offering costs of $118,113 in 1996. Other income (expense), net (including interest expense and interest income) changed from expense of ($13,200) for the three months ended September 30, 1996 to income of $34,023 for the three months ended September 30, 1997. This change was primarily attributable to the increased interest expense as a result of higher levels of borrowings prior to the IPO, and later offset in 1997 by the interest income earned on the IPO proceeds. 4 Other income (expense), net (including interest expense, interest income and amortization of discount and issuance costs) increased from ($10,046) for the nine months ended September 30, 1996 to ($47,580) for the nine months ended September 30, 1997. This increase was primarily attributable to the amortization of $145,023 of the bridge discount and deferred debt issuance costs relating to the Company's October 1996 Bridge Financing.. As a result of the foregoing, the Company incurred a net loss of $741,806 and $3,024,712 for the three months and nine months ended September 30, 1997, as compared to a net loss of $872,737 and $2,597,791 for the comparable periods in 1996. Liquidity and Capital Resources In January 1997, the Company consummated an underwritten initial public offering of 1,700,000 shares of Common Stock at an offering price of $5.00 per share and 1,955,000 warrants at an offering price of $.10 per warrant. The net proceeds to the Company were $7,018,788 after deducting issuance costs of $1,676,712. Each warrant entitles the registered holder thereof to purchase one share of Common Stock at an price of $5.00, subject to adjustment in certain circumstances, at any time through and including January 16, 2002. The warrants are redeemable by the Company, upon the consent of the Underwriter, at any time, upon notice of not less than 30 days, at a price of $.10 per warrant, provided that the closing bid quotation of Common Stock on all 30 of the trading days ending on the third day prior to the day which the Company gives notice has been at least 150% (currently $7.50, subject to adjustment) of the then effective exercise price of the warrants. Upon the closing of the IPO, the Company repaid $2,000,000 principal amount of bridge notes financing and converted the outstanding convertible notes into 100,000 shares of Common Stock. In addition, all outstanding shares of the Company's Series A Preferred Stock were converted into 1,059,600 shares of Common Stock. At September 30, 1997, the Company had cash and cash equivalents of $2,261,457, as compared to $198,277 at December 31, 1996. During the first nine months of 1996, $2,086,204 of cash was used in operating activities, principally as a result of the $2,597,791 loss incurred in the first nine months of 1996. During the first nine months of 1997, $2,844,536 of cash was used in operating activities, principally as a result of the $3,024,712 loss incurred in the first nine months of 1997 and a $727,960 decrease in accounts payable. This decrease in accounts payable resulted because in 1996 the Company incurred non-recurring accounting, legal and printing charges of $466,411 related to the IPO and the Bridge Financing and a non-recurring bonus of $80,000 paid to an officer per the employment agreement. The decrease in accounts payable was offset by $145,023 attributable to the amortization of the non cash discount associated with the Bridge Financing, and a $556,333 decrease in prepaid expenses and deferred offering costs associated with the IPO. Working capital/(deficit) at September 30, 1997 was $1,777,926, as compared to $(2,804,411) at December 31, 1996. The Company expects to incur significant expenses in connection with its operations, including expenses associated with hiring additional marketing and sales personnel and the research and development of product lines. The Company anticipates, based on its current proposed growth plans and assumptions relating to its growth and operations, that the proceeds from the IPO and planned revenues will be sufficient to satisfy the Company's contemplated cash requirements through 1997. However, there can be no assurance that the Company's funding requirements will not increase significantly as a result of unforeseen circumstances or that the Company's cash used by operating activities will not increase. If the Company is required to seek third-party sources of financing to meet its short-term or long-term funding needs, there can be no assurance that the Company would be able to obtain public or private third-party sources of financing or, if obtained, that favorable terms for such financing would be obtained. In addition, given the trading history of the Company's common stock since the initial public offering, there can be no assurance that the Company would be able to raise additional cash through the warrants or other public and/or private offerings of its common stock. The Company's capital requirements relating to the development and 5 commercialization of HealthDesk OnLine have been and will continue to be significant. Other than as described in this 10-QSB, the Company has no material commitments for capital expenditures. For the period August 28, 1992 (inception) to September 30, 1997, the Company had capital expenditures of $1,033,714 relating primarily to purchases of servers, PCs and telecommunications equipment. Part II Item 6. Exhibits and Reports on Form 8-K. a) Exhibits: 10.10 * Marketing Agreement dated as of September 30, 1997 between the Registrant and HBO & Company of Atlanta, Georgia 11.1 Statement Regarding computation of earnings per share 27 Financial Data Schedule *This exhibit has been filed separately with the Commission pursuant to an application for confidential treatment. The confidential portions of this exhibit have been omitted and marked by an asterisk. b) No reports have been filed on Form 8-K in the Quarter ended September 30, 1997. SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto authorized. HealthDesk Corporation By: /s/ Timothy S. Yamauchi Date: November 13, 1997 ----------------------- Timothy S. Yamauchi Chief Financial Officer (principal financial and accounting officer) 6 CONTENTS Page Condensed Balance Sheets as of December 31, 1996 and September 30, 1997 (unaudited).................................................... F-2 Condensed Statements of Operations for the three months and the nine months ended September 30, 1996 and 1997, and period from inception to September 30, 1997 (unaudited)............................. F-3 Condensed Statements of Shareholders' Equity (Deficit) for the years ended December 31, 1992, 1993, 1994, 1995, 1996 and the nine months ended September 30, 1997 (unaudited)........................ F-4 Condensed Statements of Cash Flows for the nine months ended September 30, 1996 and 1997 and period from inception to Septembe 30, 1997 (unaudited).................................................... F-5 Notes to Condensed Financial Statements................................... F-6 F-1 HealthDesk Corporation (a Development Stage Company) CONDENSED BALANCE SHEETS December 31, September 30 ASSETS 1996 1997 ---- ---- (unaudited) Current assets: Cash and cash equivalents.............................. $ 198,277 $ 2,261,457 Prepaid expenses and other............................. 172,294 108,069 Deferred offering and debt issuance costs.............. 492,109 ---- ------------------ ------------------ Total current assets................................ 862,680 2,369,526 Property and equipment, net.............................. 568,040 485,845 Other assets............................................. 17,517 16,267 ------------------ ------------------ Total assets.................................... $ 1,448,237 $ 2,871,638 ================== ================== LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable....................................... $ 857,428 $ 129,467 Accrued liabilities.................................... 441,076 462,133 Notes payable.......................................... 1,851,546 ---- Convertible notes payable and accrued interest......... 517,041 ---- ------------------ ------------------ Total liabilities 3,667,091 591,600 ------------------ ------------------ Shareholders' equity (deficit): Convertible preferred stock, no par value; authorized 3,000,000 shares; issued and outstanding 1,059,600 shares at December 31, 1996 and none at September 30, 1997................................................ 2,183,036 ---- Common stock, no par value; authorized 17,000,000 shares; issued and outstanding 2,530,120, and 5,392,845 at December 31, 1996, and September 30, 1997, respectively.................................. 1,946,552 11,457,505 Warrants............................................... ---- 195,687 Deficit accumulated during the development stage....... (6,348,442) (9,373,154) ------------------ ------------------ Total shareholders' equity (deficit)................ (2,218,854) 2,280,038 ------------------ ------------------ Total liabilities and shareholders' equit (deficit) $ 1,448,237 $ 2,871,638 ================== ================== The accompanying notes are an integral part of these financial statements. F-2 HealthDesk Corporation (a Development Stage Company) CONDENSED STATEMENTS OF OPERATIONS (unaudited) August 28, 1992 Three Months Nine Months (Inception) ------------ ----------- to Ended September 30, Ended September 30, September 30, ------------------- ------------------- 1996 1997 1996 1997 1997 ---- ---- ---- ---- ---- Revenue: Software development and licensing............ $ 154 $ 150,047 $ 6,170 $ 376,090 $ 1,119,629 Other......................................... ---- ---- ---- ---- 10,158 ----------- ------------ ------------ ------------ ------------ Total revenues.............................. 154 150,047 6,170 376,090 1,129,787 ----------- ------------ ------------ ------------ ------------ Costs and expenses: Product development........................... 398,823 480,477 1,194,038 1,785,408 4,495,525 Sales and marketing........................... 341,425 345,122 836,291 1,154,531 3,081,021 General and administrative.................... 119,243 100,078 562,986 412,683 1,898,113 ----------- ------------ ------------ ------------ ------------ Total costs and expenses................... 859,491 925,677 2,593,315 3,352,622 9,474,659 ----------- ------------ ------------ ------------ ------------ Loss from operations....................... (859,337) (775,630) (2,587,145) (2,976,532) (8,344,872) Interest expense................................. (15,709) ---- (33,707) (14,900) (127,232) Interest income.................................. 2,509 34,024 23,661 112,343 147,122 Amortization of discount and issuance cost associated with bridge financing............. ---- ---- ---- (145,023) (1,029,250) Other expenses................................... ---- ---- ---- ---- (14,322) ----------- ------------ ------------ ------------ ------------ Loss before income taxes.................... (872,537) (741,606) (2,597,191) (3,024,112) (9,368,554) Provision for income taxes....................... 200 200 600 600 4,600 ----------- ------------ ------------ ------------ ------------ Net loss................................... $ (872,737) $ (741,806) $ (2,597,791) $ (3,024,712) $ (9,373,154) =========== ============ ============ ============ ============ Net loss per share............................... $ (0.23) $ (0.14) $ (0.67) $ (0.59) =========== ============ ============ ============ The accompanying notes are an integral part of these financial statements. F-3 HealthDesk Corporation (a Development Stage Company) CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) Deficit Accumulated Total Preferred Stock Common Stock During the Shareholders' --------------- ------------ Development Equity Shares Amount Warrants Shares Amount Stage (Deficit) ------ ------ -------- ------ ------ ----- --------- Balances at August 28, 1992 (inception)............... ---- ---- ---- ---- ---- ----- ---- Common stock issued for cash on October 1, 1992 at $0.003 per share.......... ---- ---- ---- 960,000 $ 2,480 ---- $ 2,480 Net loss..................... ---- ---- ---- ---- ---- $ (92,744) (92,744) -------- ---------- --------- --------- ------------ ----------- ----------- Balances at December 31, 1992 ---- ---- ---- 960,000 2,480 (92,744) (90,264) Common stock issued for cash in April and May 1993 at $1.04 per share........... ---- ---- ---- 240,000 250,000 ---- 250,000 Net loss..................... ---- ---- ---- ---- ---- (190,749) (190,749) -------- ---------- --------- --------- ------------ ----------- ----------- Balances at December 31, 1993 ---- ---- ---- 1,200,000 252,480 (283,493) (31,013) Common stock issued for cash on May 2, 1994 at $1.04 per share..................... ---- ---- ---- 60,000 62,500 ---- 62,500 Net loss..................... ---- ---- ---- ---- ---- (237,022) (237,022) -------- ---------- --------- --------- ------------ ----------- ----------- Balances at December 31, 1994 ---- ---- ---- 1,260,000 314,980 (520,515) (205,535) Common stock issued in exchange for convertible debt on September 29, 1995 at $1.04 per share........ ---- ---- ---- 768,000 800,000 ---- 800,000 Common stock issued upon exercise of options in September and December 1995 at $1.04 per share........ ---- ----- ----- 102,000 106,250 ---- 106,250 Preferred stock issued for cash in November and December 1995 at $2.08 per share, net of issuance costs of $21,693.......... 939,600 $1,935,807 ---- ---- ---- ---- 1,935,807 Net loss..................... ---- ---- ---- ---- ---- (1,436,473) (1,436,473) -------- ---------- -------- --------- ------------ ----------- ----------- Balances on December 31, 1995 939,600 1,935,807 ---- 2,130,000 1,221,230 (1,956,988) 1,200,049 Common stock issued upon exercise of options on February 1, 1996 at $1.04 per share................. ---- ---- ---- 120 125 ---- 125 Preferred stock issued for cash in February 1996 at $2.08 per share, net of issuance costs of $2,771.. 120,000 247,229 ---- ---- ---- ---- 247,229 Common Stock issued for cash in October 1996 at $2.25 per share, net of issuance cost of $174,803.......... ---- ---- ---- 400,000 725,197 ---- 725,197 Net loss..................... ---- ---- ---- ---- ---- (4,391,454) (4,391,454) --------- --------- -------- --------- ------------ ----------- ----------- Balances at December 31, 1996 1,059,600 2,183,036 ---- 2,530,120 1,946,552 (6,348,442) (2,218,854) Common Stock and Warrants issued in connection with the initial public offering on January 23, 1997 (unaudited)............... ---- ---- $195,500 1,700,000 6,823,101 ---- 7,018,601 Preferred Stock converted to common stock (unaudited).. (1,059,600) (2,183,036) ---- 1,059,600 2,183,036 ---- ---- Convertible notes converted to common stock (unaudited).. ---- ---- ---- 100,000 500,000 ---- 500,000 Issuance of warrants in connection with the initial public offering (unaudited) ---- ---- 187 ---- ---- ---- 187 Common Stock issued upon exercise of options in March at $1.04 and $2.08 per share (unaudited)..... ---- ---- ---- 3,125 4,816 ---- 4,816 Net loss (unaudited)......... ---- ---- ---- ---- ---- (3,024,712) (3,024,712) --------- ---------- -------- --------- ------------ ----------- ----------- Balances on September 30, 1997 (unaudited)............... ---- ----- $195,687 5,392,845 $ 11,457,505 $(9,373,154) $ 2,280,038 ========= ========== ======== ========= ============ =========== =========== The accompany notes are an integral part of these financial statements. F-4 CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Nine Months Ended September 30, August 28, 1992 ------------------------------- (inception) to 1996 1997 September 30,1997 ---- ---- ----------------- Cash flows from operating activities: Net loss....................................... $ (2,597,791) $ (3,024,712) $ (9,373,154) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization................ 159,871 198,083 492,794 Amortization of non cash discount............ ---- 145,023 1,029,250 Other........................................ 17,254 --- 28,800 Changes in assets and liabilities: (Increase) decrease in prepaid expenses and deferred costs............................ (277,630) 556,333 (85,225) (Increase) decrease in other assets........ (37,589) 1,250 (16,267) Increase (decrease) in accounts payable.... 294,856 (727,960) 129,467 Increase in accrued liabilities............ 354,825 7,447 465,564 ---------------- ------------------ ------------------ Net cash used in operating activities..... (2,086,204) (2,844,536) (7,328,771) ---------------- ------------------ ------------------ Cash flows from investing activities: Additions to property and equipment............ (296,394) (115,888) (1,033,714) ---------------- ------------------ ------------------ Net cash used in investing activities...... (296,394) (115,888) (1,033,714) ---------------- ------------------ ------------------ Cash flows from financing activities: Payments of short-term notes payable........... ---- (2,000,000) (2,000,000) Proceeds of short-term notes payable, net accrued offering costs........................ ---- ---- 970,750 Repayment of convertible notes payable......... ---- ---- (500,000) Proceeds from issuance of convertible notes payable....................................... 500,000 ---- 1,800,000 Proceeds from issuance of common stock and warrants, net of offering costs............... ---- 7,018,788 8,058,965 Net proceeds from issuance of preferred stock.. 235,217 ---- 2,183,036 Proceeds from shareholders' loans.............. ---- ---- 118,164 Repayment of loans from shareholders........... ---- ---- (118,164) Proceeds from the exercise of stock options..... 100,125 4,816 111,191 ---------------- ------------------ ------------------ Net cash provided by financing activities... 835,342 5,023,604 10,623,942 ---------------- ------------------ ------------------ Net increase (decrease) in cash and cash equivalents................................. (1,547,256) 2,063,180 2,261,457 Cash and cash equivalents at beginning of period.. 1,554,034 198,277 ---- ---------------- ------------------ ------------------ Cash and cash equivalents at end of period........ $ 6,778 $ 2,261,457 $ 2,261,457 ================ ================== ================== The accompany notes are an integral part of these financial statements. F-5 HealthDesk Corporation (a Development Stage Company) NOTES TO CONDENSED FINANCIAL STATEMENTS (unaudited) The interim financial data is unaudited; however, in the opinion of management, the interim data includes all adjustments, consisting of all normal recurring adjustments necessary for a fair statement of results for the interim periods. The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. Operating results for the nine months ended September 30, 1997 are not necessarily indicative of the results that may be expected for the year ending December 31, 1997. The organization and the business of the Company, accounting policies followed by the Company and other information are contained in the notes to the Company's consolidated financial statements filed as part of the Company's annual report for the fiscal year ended December 31, 1996 on Form 10-KSB. This quarterly report should be read in conjunction with such annual report. For comparability, certain September 30, 1996 amounts have been reclassified where appropriate to conform to the financial statement presentation used at September 30, 1997. 1. Organization and Basis of Presentation: HealthDesk Corporation (the Company), a development stage company, is engaged in designing, developing and marketing HealthDesk(R) OnLine, a healthcare management and information system which enables consumers to take a more active role in their personal and family health. HealthDesk OnLine features easy-to-use Windows-based software designed to develop personal medical records and health management programs and access educational, health related information from the Company's private website and over the Internet. 2. Recently Issued Accounting Pronouncements: In February 1997, Statement of Financial Accounting Standards No. 128 "Earnings Per Share" (FAS 128) was issued and is effective for the Company's year ending December 31, 1997. In March 1997, Statement of Financial Accounting Standards No. 129, "Disclosure of Information About Capital Structure" was issued and is effective for the Company's year ending December 31, 1997. In June 1997, Statement of Financial Accounting Standards No. 130 "Reporting Comprehensive Income" and Statement of Financial Accounting Standards No. 131 "Disclosures About Segments of An Enterprise and Related Information" were issued and are effective for the year ending December 31, 1998. The Company has not determined the impact of the implementation of these pronouncements. 3. Legal Proceedings: The Company is subject to a complaint filed by a former employee with the California Department of Fair Employment & Housing and a second from a former consultant. The claim alleges wrongful termination as a result of alleged denial of reasonable accommodation for a wrist and neck injury. The second complaint alleges that a former consultant is entitled to compensation associated with accelerated vesting of stock options. The Company intends to defend these matters vigorously. There can be no assurance, however, that such matters will be resolved in a manner favorable to the Company. F-6 HealthDesk Corporation (a Development Stage Company) NOTES TO CONDENSED FINANCIAL STATEMENTS (unaudited) 4. Initial Public Offering: On January 23, 1997, the Company completed an initial public offering of 1,700,000 shares of Common Stock at $5.00 per share, and 1,700,000 warrants at $0.10 per warrant. Each warrant is exercisable through January 16, 2002 and allows the purchase of one share of common stock at $5.00, subject to adjustment in certain circumstances. In January 1997, the underwriter exercised its option to purchase an additional 255,000 warrants at $0.10 per warrant to cover over-allotments. The Company sold the securities to the underwriter at a discount of 10% from the initial public offering price and paid the underwriters an expense allowance of 3% of the gross proceeds of the public offering. The Company also sold, pursuant to the underwriting agreement, to the underwriters for $187, warrants to purchase up to an aggregate of 170,000 shares of Common Stock, no par value and/or 170,000 warrants to purchase 170,000 shares of Common Stock. After deducting offering expenses, the Company received net proceeds from the offering of $7,018,788. 5. Stock Options: On September 2, 1997, the Company authorized a voluntary stock option repricing program in which 20,000 stock options originally issued with an exercise price of $5.00 per share, were reissued with an exercise price of $3.25 per share, the fair market value of the Company's Common Stock on September 2, 1997. F-7 Exhibit Index Description ----------- 10.10* Marketing Agreement dated as of September 30, 1997 between the Registrant and HBO & Company of Atlanta, Georgia 11.1 Statement Regarding computation of earnings per share 27 Financial Data Schedule *This exhibit has been filed separately with the Commission pursuant to an application for confidential treatment. The confidential portions of this exhibit have been omitted and marked by an asterisk.